Immunomedics
Executive Summary
Biopharmaceutical firm receives "nonapprovable" letter from FDA for a PLA for the company's ImmuRAID-CEA colorectal cancer imaging agent. The Morris Plains, N.J. firm says May 25 that it plans to meet with the agency "promptly" to discuss issues raised in the letter and remains confident that its first product "ultimately" will be licensed